Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02002689
Title LDE225 for Patients With PTCH1 or SMO Mutated Tumors
Acronym SIGNATURE
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California Davis Cancer Center UC Davis Cancer (3) Sacramento California 95817 United States Details
Rocky Mountain Cancer Centers RMCC - Aurora Greenwood Village Colorado United States Details
Lurie Children's Hospital of Chicago Developmental Therapeutics Chicago Illinois 60611 United States Details
Minnesota Oncology Hematology, P.A. Southdate Medical Center Minneapolis Minnesota 55404 United States Details
Cleveland Clinic Foundation Cleveland Clinic (19) Cleveland Ohio 44195 United States Details
Sanford Research Sanford Health Sioux Falls South Dakota 57104 United States Details
Oncology Consultants Oncology Group Houston Texas 77024 United States Details
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) Houston Texas 77030 United States Details
Intermountain Medical Center Intermountain Healthcare Murray Utah 84157 United States Details
Seattle Cancer Care Alliance Skagit Valley Hospital Seattle Washington 98109-1023 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field